

DAFTAR PUSTAKA

1. Rudd KE, Johnson SC, Agesa KM, et al. Global , regional , and national sepsis incidence and mortality , 1990 – 2017 : analysis for the Global Burden of Disease Study. *The Lancet*. 2020;395(10219):200-211. doi:10.1016/S0140-6736(19)32989-7
2. Purba AKR, Mariana N, Aliska G, et al. The burden and costs of sepsis and reimbursement of its treatment in a developing country: An observational study on focal infections in Indonesia. *International Journal of Infectious Diseases*. 2020;96:211-218. doi:10.1016/j.ijid.2020.04.075
3. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA*. 2016;315(8):801-810. doi:10.1001/jama.2016.0287
4. Grondman I, Pirvu A, Riza A, Ioana M, Netea MG. Biomarkers of inflammation and the etiology of sepsis. *Biochemical Society Transactions*. 2020;48(1):1-14. doi:10.1042/BST20190029
5. Abe T, Ogura H, Kushimoto S, et al. Variations in infection sites and mortality rates among patients in intensive care units with severe sepsis and septic shock in Japan. *Journal of Intensive Care*. 2019;7(1). doi:10.1186/s40560-019-0383-3
6. Self WH, Balk RA, Grijalva CG, et al. Procalcitonin as a Marker of Etiology in Adults Hospitalized with Community-Acquired Pneumonia. *Clinical Infectious Diseases*. 2017;65(2):183-190. doi:10.1093/cid/cix317
7. Bassetti M, Russo A, Righi E, et al. Role of procalcitonin in predicting etiology in bacteremic patients: Report from a large single-center experience. *Journal of Infection and Public Health*. 2020;13(1):40-45. doi:10.1016/j.jiph.2019.06.003
8. Handayani N, Lardo S, Nugrohowati N. Difference of Procalcitonin Levels in Gram-Positive and Gram-Negative Bacterial Sepsis Patients of Indonesia Army Central Hospital Gatot Soebroto in 2016. *JUXTA: Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga*. 2022;13(1):38. doi:10.20473/juxta.v13i12022.38-41
9. Yan ST, Sun LC, Jia HB, et al. Procalcitonin levels in bloodstream infections caused by different sources and species of bacteria. *American Journal of Emergency Medicine*. 2017;35(4):579-583. doi:10.1016/j.ajem.2016.12.017
10. Thomas-Rüddel DO, Poidinger B, Kott M, et al. Influence of pathogen and focus of infection on procalcitonin values in sepsis patients with bacteremia or candidemia. *Critical Care*. 2018;22(1). doi:10.1186/s13054-018-2050-9
11. Ryoo SM, Kim WY. Clinical applications of lactate testing in patients with sepsis and septic shock. *Journal of Emergency and Critical Care Medicine*. 2018;2:14-14. doi:10.21037/jeccm.2018.01.13
12. Kim J sung, Kim YJ, Kim WY. Characteristics and clinical outcomes of culture-negative and culture-positive septic shock: a single-center

- retrospective cohort study. *Critical Care*. 2021;25(1). doi:10.1186/s13054-020-03421-4
13. Kara İ, Undar HN, Seven F, et al. The relationship between sepsis FOCI and procalcitonin values in intensive care patients. *Journal of Critical and Intensive Care*. 2020;11(2):42-49. doi:10.37678/dcybd.2020.2530
 14. Guntur A. Sepsis. In: *Buku Ajar Ilmu Penyakit Dalam Edisi 6.* ; 2017:4110-4115.
 15. Purwanto DS, Astrawinata DAW. Mekanisme Kompleks Sepsis dan Syok Septik. *Jurnal Biomedik*. 2018;10(3):143-151.
 16. Huang M, Cai S, Su J. The pathogenesis of sepsis and potential therapeutic targets. *International Journal of Molecular Sciences*. 2019;20(21). doi:10.3390/ijms20215376
 17. Dharaniyadewi D, Lie KC, Suhendro S. Peran Prokalsitonin sebagai Penanda Inflamasi Sistemik pada Sepsis. *Jurnal Penyakit Dalam Indonesia*. 2015;2(2):116-123.
 18. Intan S, D VS. Clinical Utility and Measurement of Procalcitonin. *The Clinical Biochemist Reviews*. 2017;38(2):59-68.
 19. Buchori, Prihatini. Diagnosis Sepsis Menggunakan Procalsitonin. *Indonesia Journal of Clinical Pathology and Medical Laboratory*. 2006;12(3):127-133.
 20. Grace E, Turner RM. Use of Procalcitonin in Patients With Various Degrees of Chronic Kidney Disease Including Renal Replacement Therapy. *Clinical practice*. 2014;59:1761-1767. doi:10.1093/cid/ciu732
 21. Long B, Koyfman A. *Ready for Prime Time? Biomarkers in Sepsis*. 1st ed. Elsevier; 2017. doi:10.1016/j.emc.2016.09.004
 22. Asati AK, Gupta R, Behera D. To Determine Blood Lactate Levels in Patients with Sepsis Admitted to a Respiratory Intensive Care Unit and to Correlate with their Hospital Outcomes. *International Journal of Critical care and Emergency Medicine*. 2018;4(2):1-14. doi:10.23937/2474-3674/1510045
 23. Dolin HH, Papadimos TJ, Chen X, et al. Characterization of Pathogenic Sepsis Etiologies and Patient Profiles: A Novel Approach to Triage and Treatment. *Microbiology Insights*. 2019;12:117863611882508. doi:10.1177/1178636118825081
 24. Clements TW, Tolonen M, Ball CG, et al. Secondary Peritonitis and Intra-Abdominal Sepsis: An Increasingly Global Disease in Search of Better Systemic Therapies. *Scandinavian Journal of Surgery*. 2021;110(2):139-149. doi:10.1177/1457496920984078
 25. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the infectious diseases society of America. *Clinical Infectious Diseases*. 2009;49(1):1-45. doi:10.1086/599376
 26. Andersen LW, Mackenhauer J, Roberts JC, et al. Etiology and therapeutic approach to elevated lactate levels. *Mayo Clinic Proceedings*. 2013;88(10):1127-1140. doi:10.1016/j.mayocp.2013.06.012

27. Gupta S, Jaswani P, Sharma RK, et al. Procalcitonin as a diagnostic biomarker of sepsis: A tertiary care centre experience. *Journal of Infection and Public Health*. 2019;12(3):323-329. doi:10.1016/j.jiph.2018.11.004
28. Phua J, Ngerng WJ, See KC, et al. Characteristics and outcomes of culture-negative versus culture-positive severe sepsis. *Critical Care*. 2013;17(5). doi:10.1186/cc12896
29. Watanabe Y, Oikawa N, Hariu M, et al. Ability of procalcitonin to diagnose bacterial infection and bacteria types compared with blood culture findings. *International Journal of General Medicine*. 2016;9:325-331. doi:10.2147/IJGM.S115277
30. Mellhammar L, Kahn F, Whitlow C, et al. Bacteremic sepsis leads to higher mortality when adjusting for confounders with propensity score matching. *Scientific Reports*. 2021;11(1). doi:10.1038/s41598-021-86346-4
31. Lever A, Mackenzie I. Sepsis: Definition, epidemiology, and diagnosis. *British Medical Journal*. 2007;335(7625):879-883. doi:10.1136/bmj.39346.495880.AE
32. Scheer CS, Fuchs C, Gründling M, et al. Impact of antibiotic administration on blood culture positivity at the beginning of sepsis: a prospective clinical cohort study. *Clinical Microbiology and Infection*. 2019;25(3):326-331. doi:10.1016/j.cmi.2018.05.016



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
 UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
 KOMITE ETIK PENELITIAN KESEHATAN
 RSPTN UNIVERSITAS HASANUDDIN
 RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
 Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
 JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.



Contact Person: dr. Agussalim Bukhari.,MMed,PhD., SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 817/UN4.6.4.5.31/ PP36/ 2021

Tanggal: 24 Desember 2021

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH21120785		No Sponsor Protokol	
Peneliti Utama	dr. Ulfa Ansolorita M		Sponsor	
Judul Peneliti	Faktor-faktor yang mempengaruhi kadar prokalsitonin dan laktat darah pada pasien Sepsis			
No Versi Protokol	1		Tanggal Versi	22 Desember 2021
No Versi PSP			Tanggal Versi	
Tempat Penelitian	RS Dr. Wahidin Sudirohusodo Makassar			
Jenis Review	<input checked="" type="checkbox"/> Exempted <input type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal		Masa Berlaku 24 Desember 2021 sampai 24 Desember 2022	Frekuensi review lanjutan
Ketua KEPK FKUH RSUH dan RSWS	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)		Tanda tangan	
Sekretaris KEPK FKUH RSUH dan RSWS	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)		Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan